Sugi Predict

Sugi Predict / Targets / CHLSN

CHLSN

Protein cholesin · Q9BRJ6 · CHLSN on Sugi Atlas →

0 patent compounds predicted against CHLSN, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CHLSN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
The Low HDL On Six Weeks Statin Therapy (LOW) Study PHASE4UNKNOWN
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer PHASE2COMPLETED
Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation PHASE2COMPLETED
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
CS-121 APOC3 Base Editing in FCS EARLY_PHASE1RECRUITING
Clinical Decision Support for Familial Hypercholesterolemia nanRECRUITING
GPR146 and Cholesterol Metabolism nanNOT_YET_RECRUITING
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom nanRECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Exome Sequencing in Autistic Spectrum Disorder nanCOMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Identification of Genes Predisposing to Atherosclerosis nanCOMPLETED
Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia nanCOMPLETED
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
A Mediterranean-style Breakfast and Postprandial Lipid Disorders in Obese Pre-adolescents and Adults nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) nanWITHDRAWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Apolipoprotein A-I Gene Polymorphism and Atherosclerosis nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals nanCOMPLETED
EAS Familial Hypercholesterolaemia Studies Collaboration nanRECRUITING
Effects of Colesevelam HCl On Bile Acid Kinetics nanCOMPLETED
Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease nanCOMPLETED
Risk Burden of Lipoprotein Metabolic Gene Haplotypes nanCOMPLETED
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHLSN binder may also engage these)

ProteinNameSimilarity
Q9CXL3 — 0.994 Q9CXL3 →
Q5I0E3 — 0.993 Q5I0E3 →
Q9NSI2 — 0.991 Q9NSI2 →
Q9UPV0 — 0.989 Q9UPV0 →
D3ZSC8 — 0.987 D3ZSC8 →
Q5I034 — 0.987 Q5I034 →
Q8N283 — 0.987 Q8N283 →
P53814 — 0.986 P53814 →
Q6DGF9 — 0.986 Q6DGF9 →
Q9DB85 — 0.986 Q9DB85 →
Q99PT3 — 0.986 Q99PT3 →
P58468 — 0.986 P58468 →
Q5TKR9 — 0.986 Q5TKR9 →
A0JMK9 — 0.985 A0JMK9 →
O43159 — 0.985 O43159 →
Q58CQ0 — 0.985 Q58CQ0 →
Q0X0C4 — 0.985 Q0X0C4 →
Q8BHL3 — 0.985 Q8BHL3 →
Q9NXH3 — 0.985 Q9NXH3 →
A0A8I3PMN2 — 0.985 A0A8I3PMN2 →
Q8VID5 — 0.985 Q8VID5 →
Q8K330 — 0.985 Q8K330 →
Q8TDY4 — 0.985 Q8TDY4 →
Q6NSJ2 — 0.985 Q6NSJ2 →
Q566C8 — 0.985 Q566C8 →
Q7TT52 — 0.985 Q7TT52 →
Q96I34 — 0.984 Q96I34 →
Q9Y4B5 — 0.984 Q9Y4B5 →
Q2TAC2 — 0.984 Q2TAC2 →
Q9Z0E3 — 0.984 Q9Z0E3 →